Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) saw unusually large options trading activity on Monday. Stock investors bought 49,767 call options on the stock. This represents an increase of approximately 424% compared to the average daily volume of 9,504 call options.
Summit Therapeutics Stock Down 9.7%
Shares of SMMT stock opened at $10.67 on Wednesday. The stock has a 50-day moving average of $16.16 and a 200-day moving average of $16.09. Summit Therapeutics has a one year low of $10.53 and a one year high of $29.23.
Institutional Trading of Summit Therapeutics
A number of large investors have recently made changes to their positions in the company. Fifth Third Bancorp increased its holdings in Summit Therapeutics by 24.4% during the 1st quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock worth $71,000 after purchasing an additional 732 shares in the last quarter. Tidal Investments LLC lifted its holdings in shares of Summit Therapeutics by 0.7% in the second quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock valued at $1,764,000 after purchasing an additional 783 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Summit Therapeutics by 2.4% in the third quarter. Russell Investments Group Ltd. now owns 42,714 shares of the company’s stock valued at $722,000 after purchasing an additional 1,021 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of Summit Therapeutics by 1.1% during the third quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock worth $1,611,000 after buying an additional 1,025 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Summit Therapeutics by 61.7% during the third quarter. GAMMA Investing LLC now owns 2,697 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares during the period. Institutional investors own 4.61% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Report on SMMT
Top Summit Therapeutics Stories
These are some of the SMMT stories that stood out recently:
- Positive Sentiment: Citigroup maintained a Buy rating while trimming its price target from $43 to $42, signaling that the analyst sees potential despite the regulatory setback. Citigroup rating
- Neutral Sentiment: Commentary describes first-line ivonescimab data as a future catalyst, while noting difficulties in the second-line setting. The data could help shape the investment outlook, but its results are not yet known. Seeking Alpha analysis
- Negative Sentiment: The FDA issued a Complete Response Letter and declined to approve ivonescimab for lung cancer. Reports say the agency found the overall-survival evidence insufficient despite positive progression-free-survival results. The decision clouds the drug’s regulatory path and contributed to shares falling to a 52-week low. Reuters report Zacks report
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading
- Five stocks we like better than Summit Therapeutics
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
